OSI Group Acquiring Other Companies So That To Increase the Global Reaches

The one thing that OSI Group has been focusing on is that they will have foreign and domestic expansion for the past five years. From the 1970s when Sheldon Lavin joined the company, he has been the reason why the company has been focused on the global expansion. The recent purchase that OSI industry has been making will be of help in increasing their reach. In 2017, they made one purchase, and that is buying the former Tyson Foods plant. The space that the company has is 200,000 square feet, and the facility will offer the company with space that will help in increasing the production to cater to the customers in North American.

The reason for the purchase is that it will be of assistance in taking care of the demand that the company had because it was growing fast. The plant was designed in a way that it will take care of the poultry products but that would not limit OSI Group in producing different types of foods. The other thing that OSI Group purchased is Flagship Europe in 2016 December that will be of help the company is reaching the people of the United Kingdom and Europe. The recent move that was made is Flagship changed their name to Creative Foods Europe the name was so that it will best describe the capabilities that the company was offering.

The first time OSI Group started off as Otto & Sons that was in 1909. The first time it started, it was just a small shop that dealt with butcher and meat supply in the Suburbs of Chicago. The first time that the company got recognition was when they were chosen by McDonald’s to supply ground beef in the restaurant that was opened in Ray Kroc. While they were still named Otto & Sons in 1973, they opened a new plant that was located in West Chicago that would offer the services of being the supplier of beef to McDonald. In 1975, there was the change of names, and that’s when the company got the OSI Group name. At the end of the 1970s, the firm had expanded to parts like Germany and Utah as they still offered there services to McDonald. Learn More.

Imran Haque’s take on Robotic Assisted Surgeries

Every part of our lives has significantly changed as a result of the advancement in technology. The medical sector and more so surgery has not been left behind. Today, technology has allowed for diagnosis and treatment of patients. Dr. Imran Haque understands this phenomenon much apparently. As a leading doctor at Horizon Internal Medicine in Asheboro, North Carolina, he has helped patients gain body wellness for the past 15 years. His area of specialty is cosmetic surgery, weight management, laser hair removal Venus body contouring as well as diabetes management.

Horizon Internal Medicine is one of the trusted clinics for primary care, considering that it has kept its pace with technological advancement necessary for medical uses. Patients who need surgery may be referred to Dr. Imran Haque since he has the necessary expertise in some treatments. Imran earned his medical degree from the Universidad Iberoamericana popularly known as UNIBE. At the Randolph hospital as well as Kindred Hospital-Greensboro, Imran Haque is a specialist. Most of his patients are impressed with his practice. They say that he is not an ordinary doctor but is rather caring, attentive, as well as experienced and has a big heart.

In the near future, Horizon Internal Medicine will be among the few medical practices that employ a robotic assisted cosmetic surgery. A doctor together with his co-workers uses a combination of electronics, computers as well as machinery to operate. A camera after that goes to the body of a patent and signals the external monitor. Imran Haque expresses his optimism that he could have this technology. Numerous studies have indicated that robotic guided cosmetic procedures are way more accurate compared to the human guided ones. The results too are way superior. Imran Haque notes that this new surgical procedure did not come to replace surgeons but instead to increase his performance through technology.

Jim Tananbaum is at the Forefront of Enabling Biotech Startups Deliver Value to Investors and Patients

Foresite Capital is an equity investment firm with a strong focus on the healthcare industry. The company provides operating capital to biotech startups to enable them to deliver innovative value that enhances patient care. Jim Tananbaum is the founder and CEO of Foresite Capital. Recently the company engaged a renowned scientific researcher, Dr. Molly He, to become a venture partner at the firm. Dr. He has over fifteen year’s research experience in pharmaceuticals and genome sequencing. Check out LinkedIn Forsite Capital

Welcoming Dr. He to the Foresite stable, Jim Tananbaum expressed confidence in her outstanding leadership. Foresite Capital was established in 2011 and is headquartered in San Francisco with an office in New York. It continues to invest in transformational biotech and pharmaceutical companies with futuristic products. The company is setting the pace in investments in biotechnology, pharmaceutical, and medical research.

Jim Tananbaum is an experienced venture capitalist. He has vast interests in over twenty healthcare companies. Some of the business he is associated with include Amerigroup, Healtheon, Amira and Jazz Pharmaceuticals among others. He is also a founding partner of several active venture capital groups such as Prospect Venture Partners I through III. He has previously held key management positions with companies such as Theravance, Sierra Ventures, and Pathwork Diagnostics.

Jim attended Yale University where he graduated with a science degree. He went to Harvard University for his medical doctor’s degree. Jim went to Harvard Business School and obtained a master’s in business administration. Additionally, he received a master’s degree from the Massachusetts Institute of Technology. Visit LinkedIn to know more.

Jim Tananbaum recently made the Forbes Midas List of top one hundred “best venture investors.” This is the third consecutive year he has received the honor. The award honors bold investment moves in futuristic biotech companies that deliver value to investors.

Dr. Tananbaum is adept at identifying strategic opportunities and driving the capital required to grow them. Through Foresite Capital, Jim Tananbaum is currently involved in several biotech companies such as Aimmune, Puma Biotechnology, and Juno Therapeutics. One of his flagship projects is Intarcia Therapeutics, a privately held Boston biotech company.

Jim Tananbaum has been instrumental in shaping Foresite Capital’s investment footprint. He has been involved in the leadership of various companies the group has funded guiding the organization structure and venture policy. More details can be found on his Crunchbase and Facebook page.